Sana Announces Upsized Pricing of Initial Public OfferingJonathan Lim, M.D.2021-02-05T11:16:49-08:00February 3, 2021|
Erasca Extends Series B Financing to $236 MillionJonathan Lim, M.D.2020-08-31T08:49:03-07:00August 31, 2020|
Inhibrx Announces Pricing of Initial Public Offering of Common StockAraceli Richardson2020-08-21T18:18:11-07:00August 21, 2020|
Halozyme Announces Roche Receives FDA Approval For Phesgo™ (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme’s ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast CancerAraceli Richardson2020-08-21T18:18:12-07:00June 29, 2020|
Sana Biotechnology Announces Completion Of Initial FinancingAraceli Richardson2020-08-21T18:18:12-07:00June 23, 2020|
SoCalGas, PG&E and Opus 12 Announce Advancements in Technology that Converts Carbon Dioxide to Renewable Natural GasAraceli Richardson2020-08-21T18:18:12-07:00June 22, 2020|
Halozyme Announces Janssen Receives European Marketing Authorization For Subcutaneous DARZALEX® Utilizing Halozyme’s ENHANZE® Technology For The Treatment Of Patients With Multiple MyelomaAraceli Richardson2020-08-21T18:18:12-07:00June 4, 2020|
CHMP recommends EU approval of Roche’s Rozlytrek for people with NTRK fusion-positive solid tumours and for people with ROS1-positive, advanced non-small cell lung cancerAraceli Richardson2020-08-18T00:57:30-07:00May 29, 2020|
U.S. Food and Drug Administration Approves DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a New Subcutaneous Formulation of Daratumumab in the Treatment of Patients with Multiple MyelomaAraceli Richardson2020-08-18T00:57:30-07:00May 1, 2020|
Health Canada approves Rozlytrek® (entrectinib) for NTRK gene fusion-positive solid tumours in locally advanced or metastatic patients(1)Araceli Richardson2020-08-18T00:57:30-07:00April 28, 2020|
Erasca Raises $200 Million Series B FinancingJonathan Lim, M.D.2020-08-31T08:52:51-07:00April 27, 2020|
